Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
IMFINZI (durvalumab)
(https://imfinzi.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Immunotherapy for Certain Cancers – IMFINZI® (durvalumab) (https://imfinzi.com)
Immunotherapy for Certain Cancers – IMFINZI® (durvalumab)
IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with NSCLC, SCLC, GC/GEJC, uHCC, BTC, MIBC and advanced or recurrent dMMR.
HEADER_HEADING_REPEATED_BODY Immunotherapy for Resectable Stage 2A-3B Non-Small Cell Lung Cancer – IMFINZI® (https://imfinzi.com/small-cell-lung-cancer.html)
Immunotherapy for Resectable Stage 2A-3B Non-Small Cell Lung Cancer – IMFINZI®
Learn about IMFINZI, an immunotherapy option for resectable Stage 2A-3B non-small cell lung cancer (NSCLC) following chemoradiation therapy.
HEADER_HEADING_REPEATED_BODY NSCLC Treatment Options – IMFINZI® (https://imfinzi.com/nsclc.html)
NSCLC Treatment Options – IMFINZI®
Learn about non-small cell lung cancer (NSCLC) treatment options, including IMFINZI, an FDA-approved immunotherapy that may be part of your treatment plan.
HEADER_HEADING_REPEATED_BODY Treatment for Stomach (Gastric) and GEJ Cancer – IMFINZI® (https://imfinzi.com/gc-gejc.html)
Treatment for Stomach (Gastric) and GEJ Cancer – IMFINZI®
Learn more about IMFINZI, a treatment used with chemotherapy for patients with stomach (gastric) and gastroesophageal junction cancer.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://imfinzi.com) Immunotherapy for Certain Cancers – IMFINZI® (durvalumab)
Sign up for support [H1] IMFINZI treats multiple types of cancer [H2] SELECT YOUR CANCER TYPE [IMG: Non-Small Cell Lung Cancer (NSCLC)] Non-Small Cell Lung Cancer (NSCLC) [IMG: Small Cell Lung Cancer (SCLC)] Small Cell Lung Cancer (SCLC) [IMG: Removable Stomach (Gastric) or Gastroesophageal Junction Cancer] Removable Stomach (Gastric) or Gastroesophageal Junction Cancer Now Approved [IMG: Unresectable Hepatocellular Carcinoma (uHCC)] Unresectable Hepatocellular Carcinoma (uHCC) [IMG: Bile Duct Cancer and Gallbladder Cancer] Bile Duct Cancer and Gallbladder Cancer [IMG: Muscle-Invasive Bladder Cancer (MIBC)] Bladder Cancer Now approved for a new type [IMG: Advanced or Recurrent dMMR Endometrial Cancer] Advanced or Recurrent dMMR Endometrial Cancer [IMG: Support through IMFINZI Treatment] Find support throughout treatment Get more information and resources for starting IMFINZI Sign up for support [IMG: close-icon] [H2] Select your SCLC stage Limited-Stage Small Cell Lung Cancer (LS-SCLC) Now Approved Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
SUB-PAGE (https://imfinzi.com/small-cell-lung-cancer.html) Immunotherapy for Resectable Stage 2A-3B Non-Small Cell Lung Cancer – IMFINZI®
Sign up for support [H1] IMFINZI is the first and only immunotherapy approved for both limited-stage and extensive-stage small cell lung cancer (SCLC) IMFINZI can help treat limited-stage small cell lung cancer that has not progressed following platinum-based chemotherapy and radiation therapy given together (cCRT) and previously untreated extensive-stage small cell lung cancer with chemotherapy.* Speak to your care team about your stage of SCLC so you can find the most helpful information here. Learn more about the stages of SCLC [IMG: See the Clinical Trial Results for LS-SCLC] See the clinical trial results for LS-SCLC [IMG: link icon] [IMG: See the Clinical Trial Results for ES-SCLC] See the clinical trial results for ES-SCLC [IMG: link icon] [IMG: See How for SCLC IMFINZI Works with other Treatments] See how IMFINZI works with other treatments [IMG: link icon] Tell me more about... Go [IMG: link icon] *Etoposide and either carboplatin or cisplatin. [IMG: close-icon] [H2] Choose your stage below: Limited-stage Small Cell Lung Cancer Extensive-stage Small Cell Lung Cancer [IMG: close-icon] [H2] Choose your stage below: Limited-stage Small Cell Lung Cancer Extensive-stage Small Cell Lung Cancer
SUB-PAGE (https://imfinzi.com/nsclc.html) NSCLC Treatment Options – IMFINZI®
Sign up for support [H1] IMFINZI could help you fight non-small cell lung cancer [H2] If you’ve been diagnosed with NSCLC, it's crucial you know all your options. IMFINZI is an FDA-approved immunotherapy that could be an important part of your personalized treatment plan. Choose a tab below I don't know my stage I know my stage FPO Doctors use a process called staging to assess the size of your cancer, where it’s located, and whether it’s spread to other parts of the body. Knowing the stage helps different specialists on your care team work together to find a treatment plan that’s right for you. [H2] Ask your care team about your options [IMG: Question Mark Icon] My doctor told me surgery is an option My doctor told me surgery is an option Even when surgery is an option, you may also be treated with immunotherapy and chemotherapy before surgery, then immunotherapy alone after. A medical oncologist can partner with your surgeon to choose a treatment plan. They can also let you know how long you'll be on treatment. Learn about IMFINZI, chemo & surgery [IMG: Question Mark Icon] My doctor told me surgery is not an option My doctor told me surgery is not an option If surgery isn’t an option, your care team may use a combination of treatments to fight your cancer, including chemoradiation therapy (CRT) then immunotherapy. In fact, IMFINZI is the #1 prescribed immunotherapy* following chemoradiation therapy for Stage 3 NSCLC that can't be removed by surgery. Learn about IMFINZI after CRT [IMG: Question Mark Icon] What if my cancer has spread? What if my cancer has spread? During the staging process, your doctors will check to see whether your cancer has spread from where it started. If it has spread to other parts of the body, your care team may use more than one immunotherapy in combination with chemotherapy. Learn about IMFINZI & IMJUDO [H6] Not sure if surgery is an option? Your doctor may recommend surgery based on the size of your cancer and if it has spread. Ask your care team whether you need any tests to find out if surgery is an option for you. *Based on US prescriptions from Jan 2019 to Jan 2025. Already know your stage? [IMG: NSCLC Stage 2A-3B Lung Icon] [H3] Stage 2A-3B cancer that can be removed by surgery Visit site #1 Prescribed Immunotherapy* FOR: [IMG: NSCLC Stage 3 Lung Icon] [H3] Stage 3 cancer—that can't be treated with surgery—following CRT Visit site [IMG: NSCLC Stage 4 Lung Icon] [H3] Stage 4 cancer that's spread to other parts of the body Visit site *Based on US prescriptions from Jan 2019 to Jan 2025. I don’t know my stage Understanding Stage 4 NSCLC How do IMFINZI + IMJUDO with chemotherapy work together? Find support for living with Stage 4 NSCLC I want to learn more about… Select a topic Side effects of IMFINZI + IMJUDO with chemotherapy Talking to my doctor about IMFINZI + IMJUDO with chemotherapy Where to get community support How to prepare for infusions Getting financial assistance Supporting my loved one Explore
SUB-PAGE (https://imfinzi.com/gc-gejc.html) Treatment for Stomach (Gastric) and GEJ Cancer – IMFINZI®
Request a care package [H1] IMFINZI is leading the way in treatment advancements for stomach (gastric) cancer or gastroesophageal junction cancer (adenocarcinoma) that can be removed with surgery. It is the first and only FDA-approved immunotherapy to be used with chemotherapy* before and after surgery, and then alone, for people with these cancer types. See the clinical trial results [IMG: See What to Expect From Treatment Icon] See what to expect from treatment [IMG: link icon] [IMG: Learn how IMFINZI + chemotherapy* Works Icon] Learn how IMFINZI + chemotherapy* work together [IMG: link icon] [IMG: Patient Support Icon] Find support [IMG: link icon] Tell me more about... Go [IMG: link icon] *Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT). [IMG: close-icon] [H2] Choose your stage below: Limited-stage Small Cell Lung Cancer Extensive-stage Small Cell Lung Cancer [IMG: close-icon] [H2] Choose your stage below: Limited-stage Small Cell Lung Cancer Extensive-stage Small Cell Lung Cancer
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /small-cell-lung-cancer.html | 0 | 0 |
| /nsclc.html | 0 | 0 |
| /gc-gejc.html | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: IMFINZI (durvalumab) (imfinzi.com)
This is a high-substance, low-BS pharmaceutical site that prioritizes regulatory compliance and clinical specificity over marketing fluff. The low score reflects a site that backs almost every indication claim with specific treatment protocols and FDA-approved contexts. The minor points are deducted for technical schema absences and repetitive heading structures rather than deceptive content.
Implement Product and Organization schema to formalize authority and link to clinical study identifiers. Add specific ClinicalTrials.gov (NCT) numbers next to the ‘See the clinical trial results’ prompts to strengthen the proof path. Consolidate repetitive H2 headings to improve structural coherence and ensure each heading provides unique value. Add a clear adverse event reporting mechanism or link to a pharmacovigilance portal in a more prominent position than the standard footer ISI.
The website perfectly aligns with the Pharma and Biotech industry, focusing on FDA-approved immunotherapy indications and regulatory-mandated safety information. The content is heavily clinical, discussing specific cancer stages like LS-SCLC and treatment regimens such as FLOT and chemoradiation therapy (CRT).
“The score of 14 is driven primarily by minor technical gaps in Identity and Authority (missing schema) and structural repetition in Information Density. The core messaging and clinical claims are highly substantiated, resulting in near-zero scores for Semantic Drift and Commodity Fingerprint.”
This training module utilizes a snapshot of public data from IMFINZI (durvalumab), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to IMFINZI (durvalumab): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://imfinzi.com to view the most current version of its content and learn from the source what this company is about and what it offers.